Hirsch, Fred R.
EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients [electronic resource] / Fred R. Hirsch. - London : Henry Stewart Talks, 2009. - 1 online resource (1 streaming video file (36 min.) : color, sound). - Cancer therapy : latest thinking in efficacy and toxicity, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules.
Access restricted to subscribers.
Mode of access: World Wide Web.
2056 Henry Stewart Talks
Biomarkers.
Neoplasms--complications.
Neoplasms--therapy.
Receptor, Epidermal Growth Factor--antagonists & inhibitors.
EGFR inhibitors in NSCLC and the role of biomarkers for selection of patients [electronic resource] / Fred R. Hirsch. - London : Henry Stewart Talks, 2009. - 1 online resource (1 streaming video file (36 min.) : color, sound). - Cancer therapy : latest thinking in efficacy and toxicity, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Cancer therapy : latest thinking in efficacy and toxicity. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: USAEGFR TKIs in 2nd /3rd line therapy -- Phase II activity of EGFR TKIs in unselected NSCLC -- BR.21 study design and overall survival -- Forest plot of survival by subsets -- Is there a survival advantage for male smokers with squamous-cell carcinoma? -- Trials comparing Gefitinib to Docetaxel -- SIGN trial -- RECIST study -- INTEREST study -- EGFR inhibitors in first line therapy -- Randomized Trials of CT+/- active targeted Rx -- Maintenance of Gefitinib WJTOG 0203 -- Cetuximab in NSCLC -- EGFR interacting molecules.
Access restricted to subscribers.
Mode of access: World Wide Web.
2056 Henry Stewart Talks
Biomarkers.
Neoplasms--complications.
Neoplasms--therapy.
Receptor, Epidermal Growth Factor--antagonists & inhibitors.